The biotech has also reported new data suggesting that may well be the case, with a six-fold reduction in neutralising antibody levels against the variant six months after a third dose of the current SpikeVax shot.
That is a much steeper decline than the 2.3-fold reduction seen with the original strain of SARS-Cov-2 over the same time period, according to Moderna, although it said antibody levels were still detectable in the study, which has been published in the New England Journal of Medicine.
